Recent developments in research
- Scientific Symposium covers hot topics in lung cancer
- Two scientists receive LCRF | Bayer lung cancer research awards
- Science Update | Summer 2025
- LCRF expands Scientific Advisory Board
- LCRF adds $3.75 million in research funding opportunities
- LCRF announces grant focused on curing EGFR+ lung cancers
Science Made Simple
- Zongertinib for HER2+ lung cancer
- Sunvozertinib for EGFR Exon 20+ NSCLC
- NeoADAURA trial shows promising results
- ADC for EGFR+ lung cancer gets accelerated approval
- New treatment for ROS1+ non-small cell lung cancer
- Accelerated approval for c-MET directed ADC
- 1-year updates from research grantees
- Inhibiting Tim-1 to enhance immunotherapy
- Science Made Simple: drug approval for NTRK
Recent FDA approvals
- FDA approves nivolumab with chemotherapy as neoadjuvant treatment for certain patients with resectable NSCLC
- Teliso-V granted FDA Breakthrough Designation for NSCLC
- 2021 FDA approvals for lung cancer treatment
- FDA approves atezolizumab for stage II to IIIA lung cancer
- FDA approves mobocertinib for EGFR exon 20 insertion+ NSCLC
- Findings and developments in the lung cancer space during the first half of 2021